Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...